Cognition Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CGTX Nasdaq 2836 www.cogrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cognition Therapeutics, Inc.

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target - Jul 1st, 2025 5:30 am
We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate - Jun 28th, 2025 8:07 am
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB) - Jun 25th, 2025 5:30 am
Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - Jun 3rd, 2025 5:30 am
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies - May 28th, 2025 5:30 am
Cognition announces outcomes from trial of zervimesine for geographic atrophy - May 9th, 2025 9:31 am
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health - May 9th, 2025 5:30 am
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - May 8th, 2025 5:30 am
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - May 7th, 2025 5:30 am
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes - Apr 1st, 2025 5:30 am
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025 - Mar 25th, 2025 5:30 am
Cognition Therapeutics Inc (CGTX) Q4 2024 Earnings Call Highlights: Strategic Focus on ... - Mar 21st, 2025 1:01 am
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update - Mar 20th, 2025 5:00 am
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - Mar 14th, 2025 6:35 am
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results - Mar 13th, 2025 2:05 pm
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing - Mar 12th, 2025 2:05 pm
Life Sciences Investor Forum Agenda Announced for March 13th - Mar 12th, 2025 11:12 am
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference - Mar 10th, 2025 5:30 am
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD - Feb 27th, 2025 5:30 am
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy - Feb 26th, 2025 5:00 am